RxDoctor Payments Data

Megan Mavromatis

Physician Assistant · Phoenix, AZNPI 1669930087

Payments from drug & device makers

$740in general payments, 2019–2025

Across 35 payments — averaging $21.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$151
  • Organon$115
  • AstraZeneca$101
  • Lilly USA, LLC$72
  • Boston Scientific$48
  • Novo Nordisk$44
  • plus $209 from 11 others

What the payments were for

  • Food & beverage$740100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$740 in reported general payments places this provider in the 65th percentile of 2,888 physician assistant providers in Arizona.

See all physician assistant providers in Arizona

Medicare billing

Part B allowed, 2024
$18,282
Medicare patients
77
Services billed
319

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide21$20,756
MounjaroTirzepatide15$19,840
JanuviaSitagliptin Phosphate12$6,252
Atorvastatin Calcium88$754
Omeprazole23$496
Gabapentin27$489
Famotidine13$328
Metformin Hcl30$289
Levothyroxine Sodium39$285
Rosuvastatin Calcium16$282
Albuterol Sulfate HfaAlbuterol Sulfate11$258
Metoprolol Succinate15$253
Paroxetine Hcl14$250
Lisinopril50$215
Amlodipine Besylate32$178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$44$20,75621 claims
Lilly USA, LLCMounjaro$72$19,84015 claims
MerckJanuvia$16$6,25212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,888 physician assistant providers in Arizona.

Other physician assistant in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →